ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ARRY Array Technologies Inc

12.96
0.50 (4.01%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Array Technologies Inc NASDAQ:ARRY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 4.01% 12.96 12.71 13.10 13.10 12.395 12.74 6,354,022 23:13:42

Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019

30/04/2019 9:05pm

PR Newswire (US)


Array Technologies (NASDAQ:ARRY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Array Technologies Charts.

BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the third quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, May 7, 2019 at 9:00 am ET.

Date: 

Tuesday, May 7, 2019

Time:

9:00 a.m. Eastern Time

Toll-Free:

(844) 464-3927

Toll:

(765) 507-2598

Pass Code:

3638409


Webcast, including Replay and Conference Call Slides:

https://edge.media-server.com/m6/p/bt2tyqof

About Array BioPharma
Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:
Array BioPharma 
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications            
(303) 381-6600
ir@arraybiopharma.com

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2019-on-may-7-2019-300840936.html

SOURCE Array BioPharma Inc.

Copyright 2019 PR Newswire

1 Year Array Technologies Chart

1 Year Array Technologies Chart

1 Month Array Technologies Chart

1 Month Array Technologies Chart

Your Recent History

Delayed Upgrade Clock